Abstract 1567P
Background
Long-term colorectal cancer (CRC) monitoring is common in Asia, but assessing colonoscopy effectiveness by adenoma detection rates (ADR) remains rare. The objective of this study was to evaluate the relationship between physician ADR and PCCRC incidence in sequential screening programs in order to provide up-to-date clinical evidence relevant to guiding CRC screening policies and practices.
Methods
This retrospective longitudinal observational study included participants (aged 40-74) with initial positive results and subsequent colonoscopy recruited from a community-based, multicenter, CRC screening program from January 2012 and December 2022 in Tianjin, China. ADR was defined as the proportion of colonoscopies in which at least 1 adenoma was detected. The primary outcome was PCCRC, defined as any CRC diagnosed 6 months after initial colonoscopy. ADR groups were categorized according to quartile distribution <42%, 42%-55%, 55%-64%, >64%), or dichotomized as at or above vs below the median for statistical analyses. PCCRC incidence rates were expressed as the number of events per 1000 person-years.
Results
Among 9957 included participants, 116 PCCRC cases were detected in 33881 person-years of follow-up. PCCRC incidence rates were per 1000 person-years were 4.34, 3.76, 2.62, and 2.69 from lowest to highest ADR group, respectively. ADR was significantly inversely associated with risk of PCCRC. Participants in the highest ADR group had 49% lower risk of PCCRC than low ADR group subjects (adjusted HR: 0.51, 95% CI 0.29-0.88). Multivariate-adjusted restricted cubic spline analyses identified a linear dose-response relationship between ADR and PCCRC risk.
Conclusions
Our findings show that ADR is inversely associated with risks of both PCCRC and interval PCCRC incidence, expanding the currently limited pool of data available for assessment of colonoscopy-based CRC monitoring programs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Natural Science Foundation of China (Grant number: 81973135), Science and Technology Commission of Shanghai Municipality (Grant number: 21XD1402600), and Tianjin Science and Technology Plan Project (Grant number: 23KPHDRC00260).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10